Startseite How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?

  • Nikolaos Thomakos ORCID logo , Stefania Dimopoulou , Maria Sotiropoulou , Nikolaos Machairiotis EMAIL logo , Anastasios Pandraklakis , Dimitrios Haidopoulos , Michalis Liontos , Aristotelis Bamias und Alexandros Rodolakis
Veröffentlicht/Copyright: 18. Dezember 2020
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

The aim of this study is to evaluate and compare outcomes of patients with mixed and pure endometrial carcinomas (MEC). We reviewed data of patients with MEC, endometroid (EC), serous (SC), and clear cell (CC) carcinomas between 2002 and 2015. Overall survival (OS) and disease-free (DF) survival rates were evaluated, according to the percentage of histologic components. Clinicopathological variables and treatment strategies were assessed. Furthermore, χ2 tests were used to compare proportions and Kaplan–Meier curves to compare recurrence and survival. Sample consisted of 302 cases with mean age 66.3 years. Early-stage disease was recorded in EC compared with CC and SC. Adnexal involvement was more frequent in MEC compared with EC (p=0.043). Extra uterine metastasis was more frequent in the SC compared to the EC group, while lymphovascular space involvement was more frequent in the MEC and CC compared to the SC (p=0.001). EC had less omentum involvement compared to CC (p=0.035) and SC (p<0.001). Furthermore, cervical involvement was more frequent in CC compared to EC (p=0.011). Recurrence (p=0.265) and OS (p=0.533) were found to be similar in MEC compared with CC, SC, and EC. Moreover, recurrence and OS were similar between EC-CC and EC-SC. There were no differences in recurrence and survival in MEC with a type II component larger than 10% or 20% (p>0.05).


Corresponding author: Nikolaos Machairiotis, Department of Obstetrics and Gynecology, Royal Surrey County Hospital, Egerton Road, Guildford, Surrey, UK GU27XX, Phone: 00447444157990, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission. All authors had an equal contribution.

  3. Competing interests: Authors declare that there is no conflict of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: Not applicable.

References

1. American Cancer Society. Cancer facts & figures 2016. Atlanta, GA: American Cancer Society; 2016.Suche in Google Scholar

2. Arnold, M, Karim-Kos, HE, Coebergh, JW, Byrnes, G, Antilla, A, Ferlay, J, et al.. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Canc 2015;51:1164–87. https://doi.org/10.1016/j.ejca.2013.09.002.Suche in Google Scholar

3. Bokhman, JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10–7. https://doi.org/10.1016/0090-8258(83)90111-7.Suche in Google Scholar

4. Zaino, R, Carinelli, S, Ellenson, LH. Tumors of the uterine corpus. WHO classification of tumors of female reproductive organs. Lyon: International Agency for Research on Cancer; 2014.Suche in Google Scholar

5. Gilks, CB, Oliva, E, Soslow, RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013;37:874–81. https://doi.org/10.1097/PAS.0b013e31827f576a.Suche in Google Scholar

6. Matrai, CE, Pirog, EC, Ellenson, LH. Despite diagnostic morphology, many mixed endometrial carcinomas show unexpected immunohistochemical staining patterns. Int J Gynecol Pathol 2018;37:405–13. https://doi.org/10.1097/PGP.0000000000000443.Suche in Google Scholar

7. Cancer Genome Atlas Research Network, Kandoth, C, Schultz, N, Cherniack, AD, Akbani, R, Liu, Y, Shen, H, et al.. For the Cancer GenomeAtlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73. doi:https://doi.org/10.1038/nature12113.Suche in Google Scholar

8. Soslow, RA, Tornos, C, Park, KJ, Malpica, A, Matias-Guiu, X, Oliva, E, et al.. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol 2019;38(1 Suppl):S64–74. https://doi.org/10.1097/PGP.0000000000000518.Suche in Google Scholar

9. Kobel, M, Meng, B, Hoang, LN, Almadani, N, Li, X, Soslow, RA, et al.. Molecular analysis of mixed endometrial carcinomas shows clonality in most cases. Am J Surg Pathol 2016;40:166–80. https://doi.org/10.1097/PAS.0000000000000536.Suche in Google Scholar

10. Roelofsen, T, van Ham, MA, Wiersma van Tilburg, JM, Zomer, SF, Bol, M, Massuger, LF, et al.. Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol 2012;120:1371–81. https://doi.org/10.1097/aog.0b013e318273732e.Suche in Google Scholar

11. Quddus, MR, Sung, CJ, Zhang, C, Lawrence, WD. Minor serous and clear cell components adversely affect prognosis in “mixed-type” endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci 2010;17:673–8. https://doi.org/10.1177/1933719110368433.Suche in Google Scholar

12. Roelofsen, T, van Ham, MA, de Hullu, JA, Massuger, LF. Clinical management of uterine papillary serous carcinoma. Expert Rev Anticancer Ther 2011;11:71–81. https://doi.org/10.1586/era.10.199.Suche in Google Scholar

13. Fader, AN, Starks, D, Gehrig, PA, Secord, AA, Frasure, HE, O’Malley, DM, et al.. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2009;115:244–8. https://doi.org/10.1016/j.ygyno.2009.07.030.Suche in Google Scholar

14. Catasus, L, Gallardo, A, Cuatrecasas, M, Prat, J. Concomitant PI3K-AKTand p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009;22:522–9. https://doi.org/10.1038/modpathol.2009.5.Suche in Google Scholar

15. Coenegrachts, L, Garcia-Dios, DA, Depreeuw, J, Santacana, M, Gatius, S, Zikan, M, et al.. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas. Virchows Arch 2015;466:415–22. https://doi.org/10.1007/s00428-015-1728-5.Suche in Google Scholar

16. Lawrenson, K, Pakzamir, E, Liu, B, Lee, JM, Delgado, MK, Duncan, K, et al.. Molecular analysis of mixed endometrioidandserous adenocarcinoma of the endometrium. PloS One 2015;J10:e0130909. https://doi.org/10.1371/journal.pone.0130909.Suche in Google Scholar

17. Rabban, J, Gilks, CB, Malpica, A, Matias-Guiu, X, Mittal, K, Mutter, GL, et al.. Issues in the differential diagnosis of uterine low-grade endometrioid carcinoma, including mixed endometrial carcinomas: recommendations from the international society of gynecological pathologists. Int J Gynecol Pathol 2019;38(Suppl 1):S25–S39, https://doi.org/10.1097/PGP.0000000000000512.Suche in Google Scholar

18. Salvesen, HB, Haldorsen, IS, Trovik, J. Markers for individualized therapy in endometrial carcinoma. Lancet Oncol 2012;13:e353–61. https://doi.org/10.1016/s1470-2045(12)70213-9.Suche in Google Scholar

19. Espinosa, I, D’angelo, E, Palacios, J, Prat, J. Mixed and ambiguous endometrial carcinomas. Aheterogenous group of tumors with different clinico-pathologic and molecular genetic features. Am J Surg Pathol 2016;40:972–81. https://doi.org/10.1097/pas.0000000000000640.Suche in Google Scholar

Received: 2020-06-21
Accepted: 2020-11-22
Published Online: 2020-12-18

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Letter to the Editor
  3. Kerala model for combating COVID-19 pandemic
  4. Original Articles
  5. Evaluation of the potential anticancer activity of different vitamin D metabolites on colorectal and breast cancer cell lines
  6. Relationship between the levels of serum fibroblast growth factor 19 and metabolic factors in obese and normal weight subjects with and without type 2 diabetes mellitus: a case-control study
  7. Early-life stress altered pancreatic Krebs cycle-related enzyme activities in response to young adulthood physical and psychological stress in male rat offspring
  8. Effect of short-term and long-term traffic noise exposure on the thyroid gland in adult rats: a sexual dimorphic study
  9. The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats
  10. Comparison of the effects of zinc oxide and zinc oxide nanoparticles on the expression of hepcidin gene in rat liver
  11. Comparison between Iberet Folic® and Zincofer® in treatment of iron deficiency anaemia in pregnancy
  12. Mini Review
  13. COVID-19 and pregnancy: are they friends or enemies?
  14. Review Articles
  15. COVID-19: a review on SARS-CoV-2 origin, epidemiology, virology, clinical manifestations and complications with special emphasis on adverse outcome in Bhopal Gas Tragedy survivor
  16. COVID-19 and neurology perspective
  17. COVID-19 and nutritional deficiency: a review of existing knowledge
  18. COVID-19 and geriatric population: from pathophysiology to clinical perspectives
  19. COVID-19 and cardiovascular disease: a review of current knowledge
  20. How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?
Heruntergeladen am 17.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/hmbci-2020-0042/html
Button zum nach oben scrollen